General Overview 18 June 2015 Exhibit 99.3

Our Vision We are a leading specialty pharmaceutical company To be the leading developer and supplier of highly potent pharmaceutical products for global markets Click above to view EirGen’s expanded facility

Ireland: Fact Sheet Waterford Cork Dublin • Population 4.2 million • Largest Exporter of Pharmaceuticals in the World, 8 th largest producer. 9 of World’s Top 10 Pharma Companies Located in Ireland • Home to 120 Pharma companies; 33 pharma and biopharma plants are FDA approved. 25,000 direct & 25,000 indirect employees serviced by excellent university programs • English speaking and excellent compliance track record • Waterford is situated in the South East of Ireland. Population of 50,000 people.

Business Overview A Specialty Pharmaceutical Company Focused on the development and commercial supply of highly potent pharmaceutical products In a purpose built, state of the art, high containment facility

Introductions – EirGen Founders PATSY CARNEY Chief Executive Officer/ Co-Founder » Co-founded EirGen » Previously Head of Operations and BD for IVAX Ireland (14 years) » Holds a BSc In Industrial Chemistry from University of Limerick and an MBA from University of Limerick TOM BRENNAN Chief Technical Officer/ Co-Founder » Co-Founded EirGen » Previously held senior  technical positions with IVAX and Stada » 10 Years IVAX Ireland as R&D Manager » Holds a BSc in Chemistry from Cork  IT, an MSc in Industrial Pharmacy from University of Manchester and an MBA from University of Limerick » Qualified Person, Six Sigma Black Belt, Packaging Technologist

EirGen Key Milestones 2005 2006 2008 2009 2011 2012 2013 Successful Regulatory Audit OPEN FOR BUSINESS Submission of First Pan EU EirGen License 1. 1 st License Approval in Canada 2. 5 th Oncology product license submitted to US FDA 3. 1 st commercial product launch in EU 1. Two oncology product licenses submitted to Japanese PMDA 2. US FDA facility approval and product approval 1. Japanese PMDA facility approval and 1 st product approval 2. US FDA Inspection, zero 483’s EirGen Founded Facility expansion complete 2014 1. US FDA Inspection, zero 483’s 2. Soft-gel fitout complete 3. 31 st clinical study complete and passed 4. 10 th ANDA submitted to US FDA 2015 1. 5 th IMB (EMA)  Inspection – no major observations 2. Acquisition by OPKO Health

Current Position: where we are now » 98 employees, all graduates » 31 successful Clinical Studies » 42 countries for commercial product supply » 27 products in R&D » 10 Products filed with US FDA to date, 3 approved » 4 Pan EU CTD Dossiers filed to date and approved » 5 Oncology Products filed with Japanese PMDA; 4 approved

Current Position: Regulatory Status » Global license submission strategy » FDA, Aug 2014, no 483’s » IMB (EMA), May 2015, no major observations » Licensed to handle Cytotoxic Materials

Therapeutic  Focus » Oncology Molecules » Immunosuppressants » Prostaglandins » Cytotoxic Molecules » Hormonals » Steroids

7 Global Presence Category Countries Commercial (BLUE) 42 Licenses Pending (ORANGE) 20 Customer Contracts (GREEN) 85

EirGen Existing Business Model R&D (non- GMP and GMP) Clinical studies and license approval Routine on- going commercial supply Sales, marketing & distribution Strategic Partner

EirGen OPKO Opportunities » API Vertical Integration - Synergies with OPKO Finetech, Israel » Product Development & Manufacturing - OPKO’s current & future products » Irish based Supply Chain Hub - global distribution of OPKO Products » Tax efficient R&D Hub - proven R&D track record since incorporation

Thank You www.EirGen.com